Austin Health

Title
[10]-gingerol induces apoptosis and inhibits metastatic dissemination of triple negative breast cancer in vivo.
Publication Date
2017-09-22
Author(s)
Martin, Ana Carolina B M
Fuzer, Angelina M
Becceneri, Amanda B
da Silva, James Almada
Tomasin, Rebeka
Denoyer, Delphine
Kim, Soo-Hyun
McIntyre, Katherine A
Pearson, Helen B
Yeo, Belinda
Nagpal, Aadya
Ling, Xiawei
Selistre-de-Araújo, Heloisa S
Vieira, Paulo Cézar
Cominetti, Marcia R
Pouliot, Normand
Subject
animal models
apoptosis
Breast cancer
cell cycle
gingerol
Type of document
Journal Article
OrcId
0000-0002-9218-9917
DOI
10.18632/oncotarget.20139
Abstract
There is increasing interest in the use of non-toxic natural products for the treatment of various pathologies, including cancer. In particular, biologically active constituents of the ginger oleoresin (Zingiber officinale Roscoe) have been shown to mediate anti-tumour activity and to contribute to the anti-inflammatory, antioxidant, antimicrobial, and antiemetic properties of ginger. Here we report on the inhibitory properties of [10]-gingerol against metastatic triple negative breast cancer (TNBC) in vitro and in vivo. We show that [10]-gingerol concentration-dependently induces apoptotic death in mouse and human TNBC cell lines in vitro. In addition, [10]-gingerol is well tolerated in vivo, induces a marked increase in caspase-3 activation and inhibits orthotopic tumour growth in a syngeneic mouse model of spontaneous breast cancer metastasis. Importantly, using both spontaneous and experimental metastasis assays, we show for the first time that [10]-gingerol significantly inhibits metastasis to multiple organs including lung, bone and brain. Remarkably, inhibition of brain metastasis was observed even when treatment was initiated after surgical removal of the primary tumour. Taken together, these results indicate that [10]-gingerol may be a safe and useful complementary therapy for the treatment of metastatic breast cancer and warrant further investigation of its efficacy, either alone or in combination with standard systemic therapies, in pre-clinical models of metastatic breast cancer and in patients.
Link
Citation
Oncotarget 2017; 8(42): 72260-72271
Jornal Title
Oncotarget

Files:

NameSizeformatDescriptionLink